Physician profile

Jesse Alan Doran

Cardiovascular Disease · Baltimore, MD

NPI 1538587704

$1,613.45

in general payments reported to CMS, 2019-2025

18 companies · $141 in 2025

The $141 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

See the full distribution for Cardiovascular Disease

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,015.07

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $327.73 2021-2025 Jardiance
Novartis Pharmaceuticals Corporation $241.05 2023-2025
Novo Nordisk INC $237.38 2023-2024 Ozempic, Wegovy
Pfizer INC. $202.49 2019-2025
E.R. Squibb & Sons, L.L.C. $191.64 2020-2025 Eliquis, Camzyos
Astrazeneca Pharmaceuticals LP $179.37 2021-2025 Farxiga
Biosense Webster, INC. $118.63 2020
Abbott Laboratories $49.10 2023-2024 Thoratec Heartmate 3 Lvas Implant Kit
Esperion Therapeutics, INC. $16.61 2021
Irhythm Technologies, INC. $16.04 2022
Philips North America LLC $15.65 2024 (Cm9) Amb Mon & Diag Und
Actelion Pharmaceuticals US, INC. $13.34 2024 Opsumit
Merck Sharp & Dohme LLC $4.42 2022

5 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$50.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jesse Alan Doran

$1,613.45

in general payments reported 2019-2025

Years
2019-2025
Top company
Boehringer Ingelheim Pharmaceuticals, INC.
Context
The $141 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/2861879/jesse-alan-doran

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.